Related references
Note: Only part of the references are listed.Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience
Massimo Aglietta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma
Hui Dong et al.
DIGESTIVE AND LIVER DISEASE (2009)
Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell
Yeh C. Linn et al.
IMMUNOLOGY (2009)
In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity
Ryosei Nishimura et al.
BLOOD (2008)
Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers
Dario Sangiolo et al.
INTERNATIONAL IMMUNOLOGY (2008)
Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas
De-Sheng Weng et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study
Martino Introna et al.
HAEMATOLOGICA (2007)
Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation
M. Introna et al.
BONE MARROW TRANSPLANTATION (2006)
Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD
F Carnevale-Schianca et al.
BLOOD (2006)
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma
N. W. C. J. van de Donk et al.
BONE MARROW TRANSPLANTATION (2006)
A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma
T Leemhuis et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells
MR Verneris et al.
BLOOD (2004)
Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning
WA Bethge et al.
BLOOD (2004)
The role of the NKG2D immunoreceptor in immune cell activation and natural killing
AM Jamieson et al.
IMMUNITY (2002)
Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production
J Baker et al.
BLOOD (2001)
CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells
RD Lopez et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2001)
ULBPs, novel MHC class I-related molecules bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor
D Cosman et al.
IMMUNITY (2001)
Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma
MR Verneris et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2001)
Expansion of cytotoxic CD3(+)CD56(+) cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation
JC Alvarnas et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2001)
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
R Childs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages
A Diefenbach et al.
NATURE IMMUNOLOGY (2000)
Share Paper
